Yes, investors here should keep an eye on the political threat to Medicare and Medicaid, since those are critical insurers in the event of FDA approval of blarcamesine and an ultimate source of a great deal of revenue for us in the U.S. Alzheimer's market.
Market Data 
Markets 
AI
